The Henne Group’s Post

Have you registered for webinar 2 of our Science Collected/ KDIGO collaboration? It's not too late to register using the following link: https://lnkd.in/ebz6BCS4 Join us at 5pm BST on 24th April, where our speakers will explore key factors to effective patient care, including a multidisciplinary approach and lifestyle modifications, as well as pharmacotherapy and the management of any treatment-associated risks in patients with #CKD. This webinar is supported by an unrestricted grant from AstraZeneca. #CKDguidelines #patientmanagement

✔️ Our Rare Disease Therapeutic Resource Center®️ (TRC) offers more than clinical ability—it provides specialty manufacturers with valuable near real-time data and analytics capabilities through the Pharma Hub Portal. This powerful platform delivers insights into therapy patterns, patient adherence, and real-world outcomes, helping manufacturers refine therapy distribution and support patient journeys more effectively. By using these data-driven solutions, we empower better decision-making and enhance patient care for complex rare conditions. Read our latest insights article for more: https://bit.ly/3Ypc56m #RareDiseaseTRC #DataandAnalytics #PharmaHubPortal #SpecialtyPharmacy

Key End Points in Clinical Trials: Panelists discuss how clinical trials in multiple myeloma can be improved to better reflect real-world scenarios and patient outcomes, emphasizing the importance of end points such as progression-free survival, overall survival, and quality of life measures, while also considering ways to increase trial inclusivity and applicability to diverse patient populations. #finance #pharmacy #lifesciences

Reflecting on recent advancements in clinical trial strategies, it's inspiring to see how data analytics are transforming the way we approach research, especially in rare diseases. By identifying key KOL and high-volume sites across multiple countries, we're enhancing our trial strategy and prioritizing patient safety and efficacy. It's exciting to be part of an era where data-driven insights are shaping the future of healthcare. I'm thrilled to be part of this evolving landscape in drug development. #DataAnalytics #ClinicalTrials #RareDisease #Healthcare #DrugDevelopment #patientsafety #kol

It is so important for HCPs and patients alike (some are both, of course😉), to be aware of the importance of PGx testing! It is a simple saliva test that will be converted into a personalised report telling the patient and their prescriber (relevant for now or in the future) which drugs will match their gene variants associated with drug metabolism. A one off test to receive the information that will be relevant for the rest of your life! At only £399, it’s a small price to pay for the knowledge that could just save your life! See mantara.co for more information. #mantara #personalisedmedicine #pharmacogenomics #pharmacogenetics

Discover a smarter approach to healthcare! 🙌 Did you know that Adverse Drug Reactions (ADRs) are responsible for 1 in 20 hospital admissions in the UK, costing the NHS a staggering £2.2 billion each year (BMJ, 2022)? 🤔 With Pharmacogenomics (PGx), we're revolutionising healthcare by tailoring medication plans to your unique genetic profile. Research shows that PGx testing can reduce clinically significant adverse drug reactions by 30% (The Lancet, 2023), so you can feel confident that you are being prescribed the right medicine for you. 💊 Say goodbye to one-size-fits-all prescriptions and hello to personalised treatment that minimises risks and maximises effectiveness. Learn more about the game-changing benefits of PGx testing on our website! 💙 #Pharmacogenomics #PrecisionMedicine #Healthcare

Up to 60% of clinical trials require biomarker info for patients to participate, but recommendations for biomarker testing to determine eligibility for clinical trials remains inconsistent. Why? We’re exploring this in an abstract and more at #ASCO24.

Resolving regulatory uncertainty is crucial for reaching a state where clinical-grade digital biomarkers are routinely used across clinical trials and clinical practice, as an integral part of patient-centric healthcare. Learn more about their evolution: https://bit.ly/3L6iX0V #clinicaltrials #biomarkers #CNS

Have you heard about the ‘adaptive designs’ concept in clinical trials? In the following post, you will find out what this idea is all about. Adaptive designs are clinical trial designs that allow for possible changes in some of their aspects. Planned modifications may be implemented based on the analysis of data collected during the trial (known as an interim analysis). 🖥️ 📊 Possible changes include the number of participants in one of the tested groups. That situation can happen in the trial comparing two new therapies, for example, A and B, with the gold standard agent. If interim analysis data show that, e.g., therapy A is definitely ineffective compared to both therapy B and gold standard, it can be withdrawn from further trial.In this way, fewer patients are recruited for less promising treatments. Other modifications to the trial can concern its length. It may be shortened if the interim analysis provides enough evidence for the effectiveness of the tested therapy. On the other hand, if the data show that there is no benefit to patients, the whole trial can be stopped earlier to minimise the risk of negative outcomes such as side effects. What do you think about this concept? Do not hesitate to share your opinions in the comments section! 👇 💬 #NeoInsight #ClinicalTrials #AdaptiveDesigns #MedicalInnovation #Research #Medicine #DrugDiscovery

Transforming Healthcare with Mira Precision PGx: Personalized Medicine for Better Outcomes Imagine a healthcare approach that’s not one-size-fits-all, but tailored to each individual’s unique genetics. ✅ Enhanced Treatment Precision Our comprehensive PGx testing customizes medication plans to each patient’s genetic profile, selecting the most effective drugs and dosages for improved outcomes, reduced side effects, and less trial and error. ✅ Reduced Adverse Drug Reactions Especially valuable for vulnerable populations, like those in long-term care, Mira Precision PGx significantly lowers the risk of adverse drug reactions (ADRs) by aligning medications with each patient’s unique biology. ✅ Improved Cost-Effectiveness With fewer ADRs and hospitalizations, PGx testing offers substantial savings—up to $4,000 per patient annually—providing clinical value and a strong financial return for healthcare providers. Learn more about how Mira Precision PGx is shaping the future of healthcare and empowering providers to make safer, more effective treatment decisions. Request more information today at https://lnkd.in/gZJKRbsS #MiraPrecisionHealth #PrecisionMedicine #PGx #PersonalizedHealthcare #BetterOutcomes #HealthcareInnovation